Inverse correlation between Interleukin-34 and gastric cancer, a potential biomarker for prognosis

Cell & Bioscience

Table 1 Correlations between IL-34, MCSF and CD68⁺ TAMs and clinical pathological features in patients with GC (n = 180)

Characteristics	Patients	IL-34		CD68		MCSF
Characteristics	Patients	Median	p	Median	p	Median	p
All cancer	180	33,827	< 0.001	1366	< 0.001	36.61	< 0.001
Noncancer (non)	159	57,921	< 0.001	246.0	< 0.001	1007	< 0.001
Gender
Male	140	37,935	0.030	1325	> 0.999	38.02	> 0.999
Female	40	14,847	0.030	1535	> 0.999	27.25	> 0.999
Age
≤ 60	79	20,658	0.048	1066	0.083	25.53	0.742
> 60	101	38,759	0.048	1702	0.083	48.79	0.742
Tumour size (diameter)
< 5 cm	87	40,818	0.358	1418	> 0.999	45.35	> 0.999
≥ 5 cm	93	24,419	0.358	1321	> 0.999	32.54	> 0.999
Lymph node metastasis
No	75	43,296	> 0.999	1715	0.169	48.20	> 0.999
Yes	105	30,495	> 0.999	1185	0.169	28.30	> 0.999
Differentiation
High	14	78,613	H/L: 0.043 H/M: 0.499 M/L: 0.495	1250	All > 0.999	223.8	H/L: 0.051 H/M: 0.471 M/L: 0.791
Moderate	78	39,376		1757		40.12
Low	88	20,788		1186		26.00
Tumour invasion depth
T1	4	87,693	All > 0.999	1762	All > 0.999	20.82	All > 0.999
T2	27	51,850		1644		26.86
T3	75	27,518		1593		40.12
T4	74	32,160		1101		39.80
TNM
I	12	22,371	I/II, I/III I/IV, II/III > 0.999 II/IV: 0.278 III/IV: 0.643	1644	I/II, I/III I/IV, II/IV III/IV > 0.999 II/III: 0.636	27.25	I/II, I/III II/III > 0.999 I/IV: 0.942 II/IV: 0.277 III/IV: 0.183
II	70	42,580		1564		48.79
III	92	32,051		1147		42.15
IV	6	6544		936.6		3.390

ISSN: 2045-3701